Betashares Space Industry ETF(RCKT.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

RCKT.AU Betashares Space Industry ETF

Not Yet Opened 10-23 16:12:00 AEDT

8.57

-0.32

-3.60%

High8.62	Low8.52	Vol30.37K
Open8.60	D1 Closing8.89	Amplitude1.12%
Mkt Cap38.14M	Tradable Cap38.14M	Total Shares4.45M
T/O260.34K	T/O Rate0.68%	Tradable Shares4.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RCKT.AU","market":"AU","secType":"STK","nameCN":"Betashares Space Industry ETF","latestPrice":8.57,"timestamp":1792732320000,"preClose":8.89,"halted":0,"volume":30373,"delay":0,"changeRate":-0.03599550056242973,"nameEN":"Betashares Space Industry ETF","floatShares":4450000,"shares":4450000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.32,"latestTime":"10-23 16:12:00 AEDT","open":8.6,"high":8.62,"low":8.52,"amount":260344,"amplitude":0.011249,"askPrice":9.03,"askSize":33,"bidPrice":8.55,"bidSize":60,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1792969200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":8.89,"nav":8.527278,"aum":39225478.001,"bidAskSpread":0,"openAndCloseTimeList":[[1792710000000,1792731600000]],"volumeRatio":0.747201652441928,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCKT.AU","preClose":8.89,"auctionPrice":8.57,"auctionVolume":5,"auction":3,"marketStatus":"盘后竞价","timestamp":1792731866931}},"requestUrl":"/m/hq/s/RCKT.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2673065675","title":"Rocket Secures Credit Facility From Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065675","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065675?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:48","pubTimestamp":1791319729,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals  said late Tuesday it has entered into a credit facility agreement with Hercules Capital  for up to $150 million, including $35 million at closing.The facility has an initial 30-month interest-only period and a 48-month maturity, with extensions available upon achievement of specified milestones, the firm said, adding that the financing also includes warrants to purchase Rocket shares.The facility will strengthen its financial position and help support its phase 2 study of RP-A501 in Danon disease and advance its broader cardiovascular pipeline, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","FXED","RCKT","PBDC","PEX","RCKT.AU","HTGC","BK4139","FBDC","BIZD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670416986","title":"Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2670416986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670416986?lang=en_us&edition=fundamental","pubTime":"2026-09-25 07:00","pubTimestamp":1790290854,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260924:nASX2QjMll","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nASXbc2DYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNDQ.AU","ASIA.AU","NDQ.AU","CLDD.AU","ARMR.AU","ATEC.AU","QNDQ.AU","RBTZ.AU","XMET.AU","ROYL.AU","RCKT.AU","BEMG.AU","HACK.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668798067","title":"Rocket Pharmaceuticals Shares Rise After Needham Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2668798067","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668798067?lang=en_us&edition=fundamental","pubTime":"2026-09-17 02:09","pubTimestamp":1789582178,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals  shares were up almost 2% in Wednesday trading after Needham upgraded the stock to buy from hold, with a price target of $9.Trading volume stood at more than 1.7 million shares, compared with a daily average of about 2 million.Price: 3.48, Change: +0.07, Percent Change: +1.91","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RCKT.AU","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667560798","title":"Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2667560798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667560798?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:53","pubTimestamp":1789555985,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals (RCKT) has an average rating of overweight and mean price target of $8.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RCKT","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667337644","title":"Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667337644","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667337644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:39","pubTimestamp":1789472373,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals  said Tuesday that it is aligned with the US Food and Drug Administration, or FDA, as it completes its phase 2 trial evaluating RP-A501 to treat Danon disease.The company said that the FDA reviewed data from the first three patients treated under a modified protocol and confirmed continued enrollment of 12 patients dosed at the recalibrated dose.The pivotal study will include 12 male patients, with the first three treated under the modified protocol counting toward the total. Rocket expects to enroll and dose the remaining nine patients by mid-2027.Rocket said it will conduct a primary assessment at 12 months using previously established co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index.Shares of the company were up 9% in Tuesday's premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LABU","RCKT","BK4139","BK4585","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658122609","title":"Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658122609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658122609?lang=en_us&edition=fundamental","pubTime":"2026-08-12 01:36","pubTimestamp":1786469782,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals' (RCKT) Q2 update confirmed its programs are on track, with management expecting regulatory updates on RP-A501 for Danon disease and RP-A601 for PKP2-ACM in H2, Wedbush Securiti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4129","LU1939255532.USD","RCKT.AU","LU1861219969.SGD","LU1861214812.USD","LU2360107325.USD","LU2244417387.USD","RCKT","LU2308191902.HKD","BK4516","LU0187121727.USD","LU0689626769.HKD","ACM","LU0124676726.USD","LU2238339852.HKD","LU2298064838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299010","title":"Wedbush Adjusts PT on Rocket Pharmaceuticals to $15 From $16, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299010","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299010?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:15","pubTimestamp":1786450548,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals (RCKT) has an average rating of overweight and mean price target of $8.84, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RCKT","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686613","title":"Units on Issue Disclosure - July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657686613?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:21","pubTimestamp":1786004479,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260806:nASX8s6Gmw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nASX8rMld1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["A200.AU","CRED.AU","ETHI.AU","HETH.AU","HYLD.AU","GGAB.AU","FOOD.AU","QBTC.AU","BNDS.AU","FAIR.AU","ARMR.AU","COMP.AU","URNM.AU","EX20.AU","QUS.AU","IIND.AU","QMAX.AU","HQLT.AU","YMAX.AU","DBBF.AU","FUEL.AU","ROYL.AU","QNDQ.AU","MTUM.AU","ASIA.AU","OOO.AU","AUDS.AU","30BB.AU","BGBL.AU","AAA.AU","UTIP.AU","CLDD.AU","DZZF.AU","ATEC.AU","BHYB.AU","QLTY.AU","WRLD.AU","RCKT.AU","HVST.AU","GBND.AU","EXUS.AU","DGGF.AU","28BB.AU","HQUS.AU","AGVT.AU","BBFD.AU","JNDQ.AU","SMLL.AU","YANK.AU","WBND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649264651","title":"Units on Issue Disclosure - June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649264651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649264651?lang=en_us&edition=fundamental","pubTime":"2026-07-06 14:11","pubTimestamp":1783318272,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260706:nASX8TXXTm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nASX96PLwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLD.AU","GAME.AU","31BB.AU","F100.AU","GBND.AU","DBBF.AU","GGAB.AU","GGFD.AU","BHYB.AU","EX20.AU","AEBD.AU","HACK.AU","ASIA.AU","A200.AU","ETHI.AU","CLDD.AU","EXUS.AU","BGBL.AU","GGOV.AU","QPON.AU","HJPN.AU","AAA.AU","QLTY.AU","US10.AU","QRE.AU","AUDS.AU","QFN.AU","QOZ.AU","USD.AU","URNM.AU","FAIR.AU","RCKT.AU","BEMG.AU","JNDQ.AU","BBAB.AU","MMKT.AU","QUS.AU","CRED.AU","DHHF.AU","BBOZ.AU","RBTZ.AU","YANK.AU","HBRD.AU","ROYL.AU","CFLO.AU","HQUS.AU","FOOD.AU","XMET.AU","UMAX.AU","BNDS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641211872","title":"Product Disclosure Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2641211872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641211872?lang=en_us&edition=fundamental","pubTime":"2026-06-05 15:14","pubTimestamp":1780643640,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260605:nASX4DpvQ6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nASXbLHRhg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RBTZ.AU","ASIA.AU","INCM.AU","RCKT.AU","QLTY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640131632","title":"Units on Issue Disclosure - May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640131632","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640131632?lang=en_us&edition=fundamental","pubTime":"2026-06-04 12:06","pubTimestamp":1780545985,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nASX8DPW3y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nASXbXWdtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBAB.AU","HETH.AU","HGBL.AU","MTUM.AU","H100.AU","HEUR.AU","A200.AU","INCM.AU","28BB.AU","HQLT.AU","QNDQ.AU","F100.AU","QOZ.AU","ATEC.AU","OOO.AU","AUST.AU","HBRD.AU","HNDQ.AU","ARMR.AU","ASIA.AU","HQUS.AU","QBTC.AU","30BB.AU","ROYL.AU","BBOZ.AU","DRUG.AU","OZBD.AU","BNKS.AU","QETH.AU","QLTY.AU","GGAB.AU","USD.AU","DRIV.AU","QAU.AU","MNRS.AU","IIND.AU","GGOV.AU","BGBL.AU","US10.AU","AEBD.AU","FUEL.AU","DBBF.AU","RCKT.AU","YANK.AU","BNDS.AU","AQLT.AU","EX20.AU","CFLO.AU","BEMG.AU","GTUM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422455","title":"Admission and Commencement of Trading - RCKT-RCK","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422455","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634422455?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:42","pubTimestamp":1778456574,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260510:nASX5cRHQv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nASX17xh3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634632214","title":"Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2634632214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634632214?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:18","pubTimestamp":1778257134,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals'  clinical and regulatory updates on its three cardiac gene therapy programs in H2 are expected to serve as \"strong\" share price catalysts, Wedbush Securities said in a note Friday.All three programs are advancing as planned, with management expected to provide an update on RP-A501 for Danon disease once alignment is reached with the US Food and Drug Administration, which should bring the program back on track, the brokerage said. A discussion of disease prevalence is critical amid questions on the size of the market opportunity, Wedbush added.For RP-A601 targeting PKP2-related arrhythmogenic cardiomyopathy, Rocket is in talks with the FDA for the final design of a potential pivotal phase 2 study, while the phase 1 study remains open due to patients' demand to undergo treatment without waiting for the next study, the brokerage said.Rocket's RP-A701 program for BAG3-associated dilated cardiomyopathy is also on track to begin a phase 1 study with a fast track desig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RCKT.AU","RCKT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0572},{"period":"1month","weight":-0.1523},{"period":"3month","weight":-0.1036},{"period":"6month","weight":-0.3879},{"period":"ytd","weight":-0.3879}],"compareEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":0.0132},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0599},{"period":"1year","weight":0.0778},{"period":"ytd","weight":0.0507}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"The Fund will seek to achieve the investment objective by adopting a “full replication” strategy. In seeking to achieve the investment objective for each Fund, the Responsible Entity will employ a passive management approach that aims to track the performance of the relevant Index, before fees and expenses.","exchange":"ASX","name":"Betashares Space Industry ETF","nameEN":"Betashares Space Industry ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Betashares Space Industry ETF(RCKT.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Betashares Space Industry ETF(RCKT.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Betashares Space Industry ETF,RCKT.AU,Betashares Space Industry ETF股票,Betashares Space Industry ETF股票老虎,Betashares Space Industry ETF股票老虎国际,Betashares Space Industry ETF行情,Betashares Space Industry ETF股票行情,Betashares Space Industry ETF股价,Betashares Space Industry ETF股市,Betashares Space Industry ETF股票价格,Betashares Space Industry ETF股票交易,Betashares Space Industry ETF股票购买,Betashares Space Industry ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Betashares Space Industry ETF(RCKT.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Betashares Space Industry ETF(RCKT.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction